Last reviewed · How we verify
NPI-0052 on Days 1, 8, 15 every 28 days
NPI-0052 on Days 1, 8, 15 every 28 days is a Small molecule drug developed by Celgene. It is currently in Phase 1 development. Also known as: marizomib, proteasome inhibitor.
At a glance
| Generic name | NPI-0052 on Days 1, 8, 15 every 28 days |
|---|---|
| Also known as | marizomib, proteasome inhibitor |
| Sponsor | Celgene |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma (PHASE2)
- Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab (PHASE1, PHASE2)
- Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer (PHASE1)
- Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NPI-0052 on Days 1, 8, 15 every 28 days CI brief — competitive landscape report
- NPI-0052 on Days 1, 8, 15 every 28 days updates RSS · CI watch RSS
- Celgene portfolio CI
Frequently asked questions about NPI-0052 on Days 1, 8, 15 every 28 days
What is NPI-0052 on Days 1, 8, 15 every 28 days?
NPI-0052 on Days 1, 8, 15 every 28 days is a Small molecule drug developed by Celgene.
Who makes NPI-0052 on Days 1, 8, 15 every 28 days?
NPI-0052 on Days 1, 8, 15 every 28 days is developed by Celgene (see full Celgene pipeline at /company/celgene).
Is NPI-0052 on Days 1, 8, 15 every 28 days also known as anything else?
NPI-0052 on Days 1, 8, 15 every 28 days is also known as marizomib, proteasome inhibitor.
What development phase is NPI-0052 on Days 1, 8, 15 every 28 days in?
NPI-0052 on Days 1, 8, 15 every 28 days is in Phase 1.
Related
- Manufacturer: Celgene — full pipeline
- Also known as: marizomib, proteasome inhibitor
- Compare: NPI-0052 on Days 1, 8, 15 every 28 days vs similar drugs
- Pricing: NPI-0052 on Days 1, 8, 15 every 28 days cost, discount & access